A Study to Determine the Safety and Tolerability of a Range of Doses of PeptiControl in Pre-diabetic Individuals
NCT ID: NCT06440213
Last Updated: 2025-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
132 participants
INTERVENTIONAL
2024-05-20
2025-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reduction of the Dietary Glycemic Index (GI) by L-Arabinose and Indigestible Dextrin
NCT01039662
To Evaluate the Impact of Consumption of a Bioactive Compound on Fasting Blood Glucose Levels in Asian Indians With Pre-diabetes
NCT06417840
The Effects of Dietary Supplements on Glycemic Control, Body Composition and Hepatic Fat Content in People With Prediabetes
NCT06437938
Anti-diabetic Effects of Persimmon Leaf Extract
NCT02706821
Glycaemic Response, Insulinaemic Response, GLP-1 and GIP Testing of Food Product Lines
NCT04610203
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This trial incorporates continuous glucose monitoring (CGM) as wearable technology to measure blood glucose and time in range of the participants for the duration of the study. The trial will be conducted over 12 days, which includes a 2 day run-in period to gather baseline CGM data, followed by 6 days of PeptiControl supplementation and 4 days follow up on safety and blood glucose tracking post supplementation.
The primary endpoint will measure safety and tolerability via adverse event reporting and occurrence of hypoglycemic episodes evaluated by time below target range (70 - 180 mg/dL) during CGM throughout the intervention.
Secondary endpoints investigated during the trial will include safety of a dose range as assessed by a safety blood panel, glucose metabolism and insulin sensitivity, time in range, aspects of cognition and memory and hunger, satiety and fullness as assessed by VAS questionnaires.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PeptiControl™ (Low - Dose 435 mg/day)
6 capsules, 30 minutes prior to lunch every day for 6 days
PeptiControl™ (Low - Dose 435 mg/day)
Plant protein hydrolysate
PeptiControl™ (Mid - Dose 870 mg/day)
6 capsules, 30 minutes prior to lunch every day for 6 days
PeptiControl™ (Mid - Dose 870 mg/day)
Plant protein hydrolysate
PeptiControl™ (High - Dose 2610 mg/day)
6 capsules, 30 minutes prior to lunch every day for 6 days
PeptiControl™ (High - Dose 2610 mg/day)
Plant protein hydrolysate
Placebo Microcrystalline Cellulose
6 capsules, 30 minutes prior to lunch every day for 6 days
Placebo Microcrystalline Cellulose
Placebo MCC micro-crystalline cellulose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PeptiControl™ (Low - Dose 435 mg/day)
Plant protein hydrolysate
PeptiControl™ (Mid - Dose 870 mg/day)
Plant protein hydrolysate
PeptiControl™ (High - Dose 2610 mg/day)
Plant protein hydrolysate
Placebo Microcrystalline Cellulose
Placebo MCC micro-crystalline cellulose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals with Body Mass Index (BMI) more than or equal to 25 and less than or equal to 33.0 kg/m²
* Individuals with fasting blood glucose (FBG) more than or equal to 100 mg/dL and less than or equal to 125 mg/dL after 8-10 hours fasting.
* Individual must be a non-smoker or an ex-smoker (5 years or more).
* Have a stable body weight (less than or equal to 4.5 kgs change) in the last 3 months (as self-reported by the individual).
* Be willing to maintain existing dietary habits and physical activity levels throughout the study period.
* Individual must be willing to wear a continuous glucose monitor during the specific time in the study
* Individual must be willing to attend all site visits and follow protocols for that visit, e.g., arrive fasting and provide blood samples.
* Individuals who have given their signed Informed Consent.
Exclusion Criteria
* Individuals having BMI outside the range of 25 - 33 kg/m².
* Individuals who are presently dieting, or who were using medications affecting body weight or who had experienced a change in weight of more than 4.5 kg or a change in physical activity within the six months preceding the screening visit.
* Individuals diagnosed with Type I Diabetes mellitus.
* Individuals diagnosed with Type II Diabetes mellitus and currently on medication.
* Individuals with Triglyceride levels more than 200 mg/dL, and/or liver function tests (AST, ALT) levels 1.5 times than the normal range, and/or kidney function test (serum creatinine) levels 1.5 times than the normal range.
* Individuals with low haemoglobin or haematocrit (i.e., lower than normal ranges \[less than 12.0 g/dL hemoglobin levels in women and less than 13.0 g/dL hemoglobin levels in men\])
* Individuals having a significant acute or chronic co-existing illnesssuch as cardiovascular disease, chronic kidney or liver disease, gastrointestinal disorder, endocrine disorder, immunological disorder, metabolic disease, or any condition which contraindicates, in the investigator's judgement, entry to the study or which poses a significant risk to the individual.
* Individuals diagnosed with hypertension (systolic blood pressure more than 140 mm Hg and/or diastolic blood pressure more than 90 mm Hg) and currently on medication.
* Individuals who have unstable medical conditions or who are on chronic medication that has not been at a stable dose for at least 1 month.
* Consumption of more than the recommended alcohol guidelines i.e., more than 21 alcohol units/week for males and more than 14 alcohol units/week for females.
* Currently or recently (within 3 months of study entry) taking any medication, which in the opinion of the investigator, could interfere with the outcome of the study, including insulin, acetylsalicylic acid, thyroxine, beta blockers, or hypolipidemic agents.
* Individuals on any medications associated with weight loss such as medication for the treatment of deficit hyperactivity, medication associated with weight gain like antipsychotics, or glucocorticoids, and/or immunosuppressants.
* Have a known allergy or sensitivity to any compounds in the test material's active or inactive ingredients or placebo.
* Individuals having a history of drug or alcohol abuse.
* Individuals who have a history of neurological disorders or significant psychiatric illness, who are cognitively impaired and/or who are unable to give informed consent.
* Present or recent use (within 3 months of pre-screening) of dietary supplements that may affect the level of blood glucose, e.g., chromium, dietary fibres, and non-digestible carbohydrates e.g., fructooligosaccharides chicory inulin, mulberry leaf extract.
* Females who are pregnant, lactating or wish to become pregnant during the study.
* Individuals with evidence of a clinically unstable disease (such as depression), as determined by medical history, physical examination, that, in the Investigator and medical monitors opinion, preclude entry into the study.
* Breast feeding women.
* Immune compromised individuals.
* Individuals who have participated in a clinical study with an investigational product (IP) within 90 days before pre-screening, or who plan to participate in another study during the study period.
30 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nuritas Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Ravindra Kulkarni, MBBS,DNB,MD
Role: PRINCIPAL_INVESTIGATOR
Ashwin Medical Foundation Pune, Maharashtra, India, 411033
Dr. Vishwajeet Gaikwad, MBBS, MD
Role: PRINCIPAL_INVESTIGATOR
Imperial Multispecialty Hospital Pune, Maharashtra, India, 411062
Dr. Nilesh Tuplondhe, MBBS, MD
Role: PRINCIPAL_INVESTIGATOR
Chopda Medicare & Research centre Nashik, Maharashtra, India, 422005
Dr. Sagar Mandlik, MBBS, MD
Role: PRINCIPAL_INVESTIGATOR
Vakratund Hospital Pvt. Ltd Nashik, Maharashtra, India, 422010
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chopda Medicare & Research Centre
Nashik, Maharashtra, India
Vakretund Hospital
Nashik, Maharashtra, India
Ashwin Medical Foundation
Pune, Maharashtra, India
Imperial Multispeciality Hospital
Pune, Maharashtra, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NRS/230703/PF/PDI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.